The drug 'Maninil': instructions for use

The drug "Maninil" instructions for use describes an effective antidiabetic drug, which according to the INN registry (international non-proprietary names) is called "Glibenclamide." This substance is the main, acting in the composition of the drug, which is manufactured by manufacturers in the form of tablets, weighing 1.75 mg or 3.5 mg. The composition of the drug as an auxiliary compound also includes lactose monohydrate, silica, food additive E 124 - dye cochineal, potato starch, gimetellose.

The pharmacokinetic properties of the drug are provided by the fact that glibenclamide, the main active substance, is contained in the preparation in micronized form. This makes it possible to increase the level of penetration of the drug and increase the area of its absorption. Also, methylhydroxyethyl cellulose, which is a part of the "Maninil" preparation, also contributes to a more effective absorption of the drug components.

Instruction for use informs that this additive has practically no effect on the state of the body, but nevertheless, it makes it possible to significantly increase the time spent in the disperse phase of the drug components, the most productive for its action. During this phase, the concentration of the drug components in the plasma increases three to five times, with a more active decrease in the amount of glucose.

The drug "Maninil" describes the instructions as a tool that has the property of rapidly absorbing from the digestive tract, and its micronized form allows the glibenclamide to be completely released from the auxiliary compounds in the body for five minutes. This effect makes it possible to take the medicine immediately before eating, 5 to 10 minutes before it. In this case, the peak concentration of the drug occurs earlier, and its effect, therefore, becomes physiological. Although in principle, the simultaneous intake of food does not have a particular effect on the action of the drug. The drug "Maninil" has a bioavailability level of 100%. His half-life from the body is an average of one and a half to three and a half hours.

The time of the stable hypoglycemic effect of glibenclamide is maintained throughout the day.

Pharmacodynamic properties of the drug "Maninil" instructions for use describes this way. This medicament is able to improve the secretion of insulin when they are absorbed by beta cells of the pancreas, and the drug enhances insulin sensitivity, which is achieved by stimulating insulin receptors.

In addition, glibenclamide is able to reduce the action of platelets, prevent ischemia of the myocardium. The drug also has a preventive effect in relation to arrhythmias.

As it is reliably established, this drug helps reduce the risk of diabetic complications (type 2), which include diabetic cardiopathy, retinopathy and nephropathy. The drug "Maninil" instructions for use describes how to reduce the level of mortality in diseases associated with diabetes.

The main indications for the use of glibenclamide are type 2 diabetes, in cases when diet therapy showed an unsatisfactory result of treatment. Tablets "Maninil" can be used as an independent therapeutic agent, and as part of a combination treatment together with other antidiabetic drugs.

It should be borne in mind that the duration of the drug and the amount of the dose is determined by the doctor on the basis of an individual approach to the patient's condition. At the initial stage of treatment, smaller doses of medication are prescribed. Then the correction of the regimen is carried out together with the correction of the diet. For detailed information on drug regimens, see the instructions for use.

The main criterion for correcting doses is the level of glucose.

The intake of glibenclamide can cause side effects, the most frequent of which is hypoglycemia. Its symptoms are sudden sweating, shaking, headache, neurological disorders and others.

Contraindications for the use of the drug are hypersensitivity to the components, secondary inefficiency of treatment with Maninil, ketoacidosis, functional disorders of the kidneys and liver.

There is insufficient information on the use of the drug by children, whose age does not exceed 18 years.

Do not use the medication during lactation and during pregnancy.

Store the drug at a temperature of not more than +25 C. If the storage conditions are met, the expiration date of the medicament is 3 years.